Výsledky vyhledávání

Akademický článek

First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.

Autor: Peterlin P; Hematology Department, Nantes University Hospital, Nantes, France., Saada-Bouzid E; Department of Medical Oncology, Cote d'Azur University, Centre Anticancer Antoine Lacassagne, Nice, France., Moskovitz M; Division of Oncology, Thoracic Cancer Service, Haifa, Israel.; Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel., Pigneux A; Department of Hematology, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France., Yuda J; Department of Hematology and Experimental Therapeutics, National Cancer Center Hospital East, Chiba, Japan., Sinnollareddy M; AbbVie Inc, North Chicago, IL, USA., Henner WR; AbbVie Inc, San Francisco, CA, USA., Chen D; AbbVie Inc, San Francisco, CA, USA., Freise KJ; AbbVie Inc, North Chicago, IL, USA., Leibman RS; AbbVie Inc, San Francisco, CA, USA., Avigdor A; Division of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center, Ramat Gan, Israel.; Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel., Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of Pulmonary Medicine and Medical Oncology, Wakayama Medical University Hospital, Wakayama Medical University Graduate School of Medicine, Wakayama, Japan.

Publikováno v: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2024 Sep; Vol. 24 (9), pp. 893-904. Date of Electronic Publication: 2024 Jul 10.

Zobrazit plný text záznamu

Akademický článek

ABBV-319: a CD19-targeting glucocorticoid receptor modulator antibody-drug conjugate therapy for B-cell malignancies.

Autor: Chang CA; AbbVie Bay Area, South San Francisco, CA., Emberley E; AbbVie Bay Area, South San Francisco, CA., D'Souza AL; AbbVie Bay Area, South San Francisco, CA., Zhao W; AbbVie Bay Area, South San Francisco, CA., Cosgrove C; AbbVie Inc, North Chicago, IL., Parrish K; AbbVie Inc, North Chicago, IL., Mitra D; AbbVie Inc, North Chicago, IL., Payson E; AbbVie Bay Area, South San Francisco, CA., Oleksijew A; AbbVie Inc, North Chicago, IL., Ellis P; AbbVie Inc, North Chicago, IL., Rodriguez L; AbbVie Inc, North Chicago, IL., Duggan R; AbbVie Inc, North Chicago, IL., Hrusch C; AbbVie Inc, North Chicago, IL., Lasko L; AbbVie Inc, North Chicago, IL., Assaily W; AbbVie Bay Area, South San Francisco, CA., Zheng P; AbbVie Bay Area, South San Francisco, CA., Liu W; AbbVie Bay Area, South San Francisco, CA., Hernandez A Jr; AbbVie Bioresearch Center, Worcester, MA., McCarthy K; AbbVie Bioresearch Center, Worcester, MA., Zhang Z; AbbVie Bay Area, South San Francisco, CA., Rha G; AbbVie Inc, North Chicago, IL., Cao Z; AbbVie Inc, North Chicago, IL., Li Y; AbbVie Inc, North Chicago, IL., Perng O; AbbVie Bay Area, South San Francisco, CA., Campbell J; AbbVie Bay Area, South San Francisco, CA., Zhang G; AbbVie Bay Area, South San Francisco, CA., Curran T; AbbVie Bay Area, South San Francisco, CA., Bruncko M; AbbVie Inc, North Chicago, IL., Marvin CC; AbbVie Inc, North Chicago, IL., Hobson A; AbbVie Bioresearch Center, Worcester, MA., McPherson M; AbbVie Bioresearch Center, Worcester, MA., Uziel T; AbbVie Inc, North Chicago, IL., Pysz MA; AbbVie Bay Area, South San Francisco, CA., Zhao X; AbbVie Bay Area, South San Francisco, CA., Bankovich A; AbbVie Bay Area, South San Francisco, CA., Hayflick J; AbbVie Bay Area, South San Francisco, CA., McDevitt M; AbbVie Bay Area, South San Francisco, CA., Freise KJ; AbbVie Inc, North Chicago, IL., Morgan-Lappe S; AbbVie Inc, North Chicago, IL., Purcell JW; AbbVie Bay Area, South San Francisco, CA.

Publikováno v: Blood [Blood] 2024 Aug 15; Vol. 144 (7), pp. 757-770.

Zobrazit plný text záznamu

Akademický článek

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma.

Autor: D'Souza A; Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI., Shah N; Division of Hematology and Oncology, University of California, San Francisco, San Francisco, CA., Rodriguez C; Medical Oncology and Hematology, Wake Forest University School of Medicine, Winston-Salem, NC., Voorhees PM; Plasma Cell Disorders Division, Department of Hematologic Oncology & Blood Disorders, Levine Cancer Institute, Atrium Health/Wake Forest Baptist, Charlotte, NC., Weisel K; Department of Oncology, Hematology and Bone Marrow Transplantation with Section of Pneumology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Bueno OF; AbbVie, Inc, North Chicago, IL., Pothacamury RK; AbbVie, Inc, North Chicago, IL., Freise KJ; AbbVie, Inc, North Chicago, IL., Yue S; AbbVie, Inc, North Chicago, IL., Ross JA; AbbVie, Inc, North Chicago, IL., Polepally AR; AbbVie, Inc, North Chicago, IL., Talati C; AbbVie, Inc, North Chicago, IL., Lee S; AbbVie, Inc, North Chicago, IL., Jin Z; AbbVie, Inc, North Chicago, IL., Buelow B; TeneoBio, Inc, Newark, CA., Vij R; Washington University School of Medicine, St Louis, MO., Kumar S; Department of Hematology, Mayo Clinic, Rochester, MN.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2022 Nov 01; Vol. 40 (31), pp. 3576-3586. Date of Electronic Publication: 2022 Aug 27.

Zobrazit plný text záznamu

Akademický článek

Margin of safety of extended-duration transdermal buprenorphine solution following multiple-dose administrations to cats.

Autor: Clark TP; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA., Linton DD; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA., Freise KJ; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA., Reinemeyer C; East Tennessee Clinical Research, Inc., Rockwood, Tennessee, USA., Newkirk KM; College of Veterinary Medicine, Biomedical and Diagnostic Sciences Department, University of Tennessee, Knoxville, Tennessee, USA., Aulbach A; MPI Research, Inc., Mattawan, Michigan, USA., Lin TL; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.

Publikováno v: Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2022 Jul; Vol. 45 Suppl 1, pp. S67-S84.

Zobrazit plný text záznamu

Akademický článek

Multicentered masked placebo-controlled phase 2 clinical study of an extended duration transdermal buprenorphine solution for postoperative pain in cats.

Autor: Clark TP; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA., Linton DD; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.; Deborah D. Linton, DL Veterinary Consulting, LLC, Rotonda West, Florida, USA., Freise KJ; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.; Kevin J. Freise, AbbVie Inc., North Chicago, Illinois, USA., Lin TL; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.; Ting-Li Lin, Briostat, LLC, Madison, Wisconsin, USA.

Publikováno v: Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2022 Jul; Vol. 45 Suppl 1, pp. S40-S51.

Zobrazit plný text záznamu

Akademický článek

Multicentered masked placebo-controlled phase 3 clinical study of an extended duration transdermal buprenorphine solution for post-operative pain in cats.

Autor: Clark TP; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA., Linton DD; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.; Deborah D. Linton, DL Veterinary Consulting, LLC, Florida, USA., Freise KJ; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.; Kevin J. Freise, AbbVie Inc., North Chicago, Illinois, USA., Lin TL; Nexcyon Pharmaceuticals, Inc., Madison, Wisconsin, USA.; Ting-Li Lin, Briostat, LLC, Madison, Wisconsin, USA.

Publikováno v: Journal of veterinary pharmacology and therapeutics [J Vet Pharmacol Ther] 2022 Jul; Vol. 45 Suppl 1, pp. S52-S66.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání